Treating Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density With Denosumab or Zoledronic Acid
Condition(s):Idiopathic Inflammatory Myopathies; Osteoporosis, OsteopeniaLast Updated:July 26, 2019Unknown status
Hide Studies Not Open or Pending
Condition(s):Idiopathic Inflammatory Myopathies; Osteoporosis, OsteopeniaLast Updated:July 26, 2019Unknown status
Condition(s):LeiomyosarcomaLast Updated:March 7, 2024Recruiting
Condition(s):OsteoporosisLast Updated:February 21, 2021Completed
Condition(s):Osteoporosis; Osteoporosis, Postmenopausal; Osteopenia; Bone LossLast Updated:November 4, 2022Recruiting
Condition(s):Osteoporosis; Osteonecrosis; Acute Lymphoblastic LeukemiaLast Updated:August 22, 2018Withdrawn
Condition(s):OsteoporosisLast Updated:September 20, 2019Completed
Condition(s):Use of Zoledronic Acid in Breast CancerLast Updated:December 21, 2021Unknown status
Condition(s):Multiple MyelomaLast Updated:November 4, 2010Completed
Condition(s):Arthritis, RheumatoidLast Updated:February 22, 2019Terminated
Condition(s):AdenocarcinomaLast Updated:September 22, 2014Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.